Inhibition of phosphodiesterase-5 and nitric oxide similarly reduce pulmonary artery pressure at high altitude  by Brunner-La Rocca, Hans P. et al.
JACC March 19,2003 ABSTRACTS - Vascular Disease, Hypertension, and Prevention 257A 
treated cells, a number of differentially expressed transcripts were identified and cloned. 
Sequence homology search revealed and matched the identified clones to 1) a small 
subset of genes known to be involved in angiogenesis, e.g. platelet endothelial cell adhe- 
sion molecule 1 (PECAM-I), matrix metalloproteinase 2 (MMP2), endothelin converting 
enzyme 1 (ECE-I), and vascular endothelial growth factor receptor 2 (VEGFR-2); 2) a 
large subset of known genes with known function, but not involved in angiogenesis to 
date; and 3) about 5-10% of the clones were novel genes with unknown function, such as 
a putative G-protein coupled receptor. Thus there are clusters of related gene products, 
differentially regulated and involved with cholinergic, proliferative and apoptotic action. 
cDNA rmcroarray analysis (-48,000 elements) validated our findings Conclwon: Nico- 
tme promotes angiogenesis through stimulation of angiogenic mechanisms partly 
through the cholinerglc pathway. Therapeutic modulation of nAChR may be useful in dls- 
orders of angiogenesis. 
9:45 a.m. 
804-3 Relation Between the C,,,T Transition in the 
Methylentetrahydrofolate Reductase Gene, Plasma 
Homocyst(e)ine and Folate Levels, and Coronary Artery 
Disease in the GENICA (Genetic and Environmental 
Factors in Coronary Atherosclerosis) Study 
Gian Paolo ROSSI, Maurizto Cesarl, Albert0 Burlina, Stefania Colonna, Mario Zanchetta, 
Gluseppe Maiollno, Pietro Maiolino, Achille Cesare Pessina, Clinica Medica 4, Padova, 
Italy, Cittadella, Italy 
Background: Hyperhomocyst(e)inemia has been implicated in atherosclerws and can 
be determined by multiple environmental and genetlc factors. However, the relationship 
of the plasma levels of homocyst(e)ine (Ho) and folate (F) with the C?“T methylentet- 
rahydrofolate reductase (MTHFR) gene polymorphism and coronary artery disease 
(CAD) has never been investigated in a large clinlcal dataset. Methods: In 964 consecu- 
tive patients (63iiO yrs. 74% men and 26% women) of the “GENICA” study, who under- 
went coronary anglography for suspected CAD, we measured HO and F by HPLC and a 
chemilummescence method, respectively. All were genotyped for the d”T MTHFR 
gene polymorphism by fluorescent PCR and melting curve analysis (LightCycls+). 
ResuI1s: We found a highly significant (p<O.OOOl) inverse relationship between Ho and 
F. A multivariate analysis identified serum creatinine, Cs”T MTHFR genotypes, F, left 
ventncular election fraction, age, and an interaction between Cs7’T MTHFR genotypes 
and F, as significant predictors of Ho (Re0.16, p<O.OOOl). When the effect of the T 
MTHFR allele was examined according to a recessive model, significantly (pcO.0001) 
higher Ho values were seen in TT (14.9eO.6 Mmol/l) than in CC+CT (12.0r0.3 pmolll) 
patients. At variance no signlflcant difference was seen between patients with (14.0r0.6 
umol/l) and wthout CAD (I 3.OtO.4 ~molll). x2 analysis showed that high Ho (z-15 pmol/l) 
were more common than expected in patients with history of previous myocardial infarc- 
tion (p=O.O03), peripheral vascular disease (p<O.OOl), vascular surgery (p<O.OOl) and 
chronic renal failure (p<O.OOl). No associations of the C?“T MTHFR polymorphism with 
such outcomes were seen. Conclusions: These results, in patients with angiographl- 
tally-assessed CAD, support the contentlon of Ho being determined by multiple factors, 
including the Cs”T transItion in the MTHFR gene. Furthermore, they indicate that hyper- 
homocyst(e)inemia. but not the C?“T MTHFR alleles, are associated with cardiovascu- 
lar outcomes albeit not with anglographically assessed CAD. 
IO:00 a.m. 
804-4 Endothelin-1 Induces Expression of Functional CD40 on 
Human Vascular Smooth Muscle Cells 
Michael Browatzki. Caroline A. Pfeiffer, Roger Kranzhbfer, University of Heidelberg, 
Heidelberg, Germany 
Background: Chronic inflammation of the vessel wall IS a hallmark of atherosclerosis. 
This inflammatory process is maintalned by a variety of cytokines generated in the vessel 
wall. Recently, activatmn of vascular cells by cell-cell contact via the CD40lCDl54 sys- 
tem has been identified as Important pathway of inflammatory stimulation in atherogene- 
sis. Human vascular smooth muscle cells @MC) as important cellular component of the 
atherosclerotic plaque can express both cytokines and the CD40/CDl54 system. On the 
other hand, the vasoactve peptide endothelin-1 (ET-l) is supposed to contribute to 
atherogenesis. This study investigated whether ET-l stimulates the inflammatory 
response in SMC via a CD40/CD154 dependent pathway. Methods and Results: ET-l 
(10 nM max) like the positive stimulus interieron-gamma (100 U/ml) increased CD40 
mRNA and protein expression after 24 hours in human SMC. This ET-l effect was medi- 
ated by the ET-A-receptor subtype since BQ-123, a selective ET-A receptor antagonist, 
prevented ET-l-induced CD40 upregulatlon whereas BQ-788. an ET-B-receptor antago- 
nist, did not (10 pM each). ET-l also activated the proinflammatory transcription factors 
NF-kappaB and AP-1 in a time dependent manner. The specific proteasome inhibitor PI- 
1 (50 PM) and a NF-kappaB decoy oligodesoxynucleotide prevented ET-l-induced CD40 
expression demonstrating dependence of this ET-1 effect on NF-kappa6 activation To 
test the functional relevance of the CD40 expression, SMC were premcubated with IO 
nM ET-1 for 24 hours and afterwards stimulated with recombinant CD154 (5 ng(ml). 
Release of Interleukin-6 (IL-6) into the culture medium was assessed by ELISA. Cells 
preincubated with ET-1 secreted a slgniflcantly higher amount of IL-6 under CD154 stim- 
ulation than control cells (265 +/- 4 vs 147 +/- 8 pglml, p < 0.05). Conclwon: ET-l 
induces an inflammatory response I” human SMC wa direct cell-cell contact which is 
medlated by the CD40ICD154 system. This mechanism may contribute to the pathogen- 
esis of atherosclerosis. 
10:15 a.m. 
804-5 Decreased Caveolin-l Expression in Atheroma: Loss of 
Antiproliferative Control of Vascular Smooth Muscle 
Cells in Human Atherosclerosis 
Carsten Schwencke, Alexander Schmeisser. Rolf Wachter, Brigina Week, Rainer 
Marquetant, Michael Kasper, Ruth H. Strasser, University of Technology Dresden, 
Dresden, Germany 
Background: Proliferation of vascular smooth muscle cells (VSMC) is involved in the 
pathogenws of primary atherosclerosis and restenosis after angioplasty. On the back- 
ground of the recently proposed antiproliferative actiwties of caveolm1 the present study 
investigated the expression of caveolin- in proliferating VSMC in vitro and especially in 
human atheroma. 
Methods and Results: Primary VSMC express high levels of caveolin- as shown by 
immunoblotting. Supplementation of serum or growth factors such as PDGF caused a 
decrease in caveolin- expressjon in VSMC. Cell-cycle entry was documented by a 
decrease of the Cdk inhibitor p27kipl and an increase of the proliferating cell nuclear 
antigen (PCNA). We further investigated the expression of caveolin- in VSMC of human 
atheroma using immunohistochem&y. In contrast to control vessels, caveolin- was 
markedly decreased in sections derived from human atheroma. The proliferation of 
VSMC m atheroma was confirmed by an increased PCNA immunostaining. 
Conclusion:Thls newly characterized decreased expression of caveolin- both in prolif- 
erating smooth muscle cells in vitro and in human atheroma in viva strongly links the loss 
of the antiproliferative control by caveolin- to the development of atherosclerosis, sug- 
gesting a pivotal role of caveolin- in the pathogenesis of atherosclerosis. 
ORAL CONTRIBUTIONS 
811 Pulmonary Hypertension and Pulmonary 
Embolism: Clinical Insights 
Monday, March 31, 2003, 11:OO a.m.-12:15 p.m. 
McCormick Place, Room S102 
1 l:oo a.m. 
811-1 Pulmonary Artery Systolic Pressure in 
Echocardiographically Normal Subjects 
Richard V Milani, Carl J. Lavie, Yvonne E. Gilliland. Krishnamoorthy Vivekananthan. 
Mark M. Cassidy, Jose Albert0 Bernal, Ali Morshedl, Ochsner Clinic Foundation, New 
Orleans, LA 
Backgrond: Pulmonary hypertension (PHTN) has undergone renewed interest of late 
with the increasing prevalence of obesity and the reported association of various anorec- 
tic agents and its subsequent effect on the pulmonary vasculature. Recent enhance- 
ments I” echocardiographic instrumentation, has refined the detection of small degrees 
of tricuspid regurgitation in subjects, and mild “elevations” of pulmonary artery systolic 
pressure (PASP) are now a common finding, resulting in concern as to whether this rep- 
resents true pathology. Previous definitions of PHTN suggested that PASP exceeding 30 
mmHg were pathologic, however this data was often derived from small numbers of rela- 
tively young patients. 
Methods: We have analyzed PASP from our echocardiographic database of 35,815 sub- 
jects, resulting in 2,472 subjects (mean age 54.9 +I- 16.3 years) which met the echo cri- 
teria of normal hearts, defined as: normal left and right ventricular dimension and 
function; normal left and right atrial dimensions; absence of aortic root dilatation or peri- 
cardial disease; absence of valvular stenosis; absence of valvular insufficiency less than 
moderate. 
Results: The mean PASP was 33.1 +/- 7.7 mmHg, and correlations were found wth age 
(p=O.OOOl), male gender (p=O.O025), septal wall thickness (p=O.OOOl) and posterior wall 
thickness (p=O.OOOl). 60% of this population had a PASP > BOmmHg, and 22% of those 
older than 50 years, and 20% of those with BMI > 30 kgIm2, had a PASP > 40mmHg. 
Conclusions: Elevations of PASP is relatively common in echocardiographically normal 
populations and correlate to age and BMI. Previous definitions of normal PASP should 
be revised to adjust for age. 
11:15 a.m. 
811-2 Inhibition of Phosphodiesterased and Nitric Oxide 
Similarly Reduce Pulmonary Artery Pressure at High 
Altitude 
Hans P. Brunner-La Rocca Patrick Egger, Oliver Senn, Manuel Ftschler, Rahel 
Thalmann, Konrad Bloch, Marco Magglorini, Unwersity Hospital, Zurich, Switzerland, 
Uwersity Hospital, Basel, Switzerland 
Background At high altitude, hypoxia induces pulmonary hypertension which plays an 
Important role in the pathophysiology of high-altitude pulmonary edema. Inhaled nitric 
oxide (NO) was shown to reduce pulmonary artery pressure (PAP), but it is not applica- 
ble in parctlce. Therefore, we investigated the effects of the PDEB-Inhibitor sildenafil (Sil) 
on PAP at high altitude in comparison with Inhaled NO. 
Methods Doppler-echocardiography was performed in 22 healthy mountaineers (10 W, 
12 M, age 29*12y; Q-saturation 75*3%) 3 hours after they reached an altitude of 
4559m. Measurements were repeated after NO (40ppm), Sil (50mg), and Sil plus NO. 
PAP was estimated from trtcuspid regurgitation and pulmonary vascular resistance 
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(PVR) from a previously described formula using preejectlon time, acceleration time and heart failure, and sudden death. The recovery of circadian regulation of HRV detected 
total systolic time. Right atrial pressure (RAP) was estimated from respiratory change of after long-term TS may be mediated by an improvement in central hemodynamics as a 
the vena cava inferior. result of TS therapy. 
Results: see table. ‘p<O.O5 vs baseline, fp<0.05 vs. NO / Sil. On the next morning, mea- 
surements returned to baseline values. “T 
LOW/HIGH FREOUENCY RATIO 
Conclusion : Inhibition of PDE-5 reduces pulmonary hypertension to a similar extent as 
NO. As expected, the 2 agents have synergistic effects. Thus, PDE-5 inhibitors may be 
candidates for prevention of high-altitude pulmonary edema in susceptible mountaineers. 
PAP 
PVR 
RAP 
Baseline 
44tlO 
84+20 
5.9il.3 
NO Sil SiI+NO Sig. 
32&’ 33*6’ 28*5^f <0.0001 
72+27 67+22 64*27’ 0.002 
5.3il.4 4.7il.l’ 3.8i1.3’ 0.03 
1 I:30 a.m. 
811-3 Prognostic Value of Transthoracic Echocardiography in 
Massive Pulmonary Embolism: A Retrospective Study 
of 617 Patients 
HOUR 
Gerard D. Pacouret E. Hamel, M. Montout. D. Djeffal Vincentelli, 6. Charbonnier, 
Trousseau Hospital, Tours, France 
Noon 
Right ventricular dilation induced by massive pulmonary embolism (PE) can be easily 
detected, at bedside, by trans-thoracic echocardiography (EC). To test the prognostic 
value of this parameter, we retrospectively analyzed a population of 617 consecutive 
patients admitted to our institution for acute massive PE, and who were evaluated by EC 
at baseline. Massive PE was defined as angiographic Miller index t 20/34 and/or pedu- 
sion lung scan defect 2 40 % and/or bilateral central PE on helicoidal CT scan. 
Results : Right ventricle/left ventricle end diastolic diameter ratio (RVILV), calculated 
from the long axis parasternal view, the subcostal view or the apical 4 chamber view in 
supine position was assessable in 546 patients ( 89 % ), 27 pts died during the index 
hospitalization (4.4 %). Univariate analysis revealed that among 7 parameters, only sys- 
temic hypotension and RV/LV were significantly associated with the risk of death (see 
table). 
After adjustment to systemic hypotension, contra-indication to thrombolysis and throm- 
bolysis, RVILV appeared as an independent predictor of in-hospital death (p=O.O06) in 
multivariate analysis. 
Conclusion : RVILV end-diastolic diameter ratio is an independent predictor of in-hospi- 
tal death in patients suffering from acute massive PE. Thrombolysis could be beneficial in 
such patients when RVILV > 0.8, even in the absence of hypotension. A prospective ran- 
811-5 Long-Term Survival Comparison in Patients With 
Primary and Secondary Pulmonary Arterial 
Hypertension Treated With Chronic Epoprostenol 
Therapy 
Maninder S. Sedi, Jessica Spates-Panyon, Michael M. Mathier. AJOY Kapoor. Guy A. 
MacGowan, Dennis M. McNamara, Srinivas Murali, University of Pittsburgh, Ptttsburgh, 
PA 
Pulmonary arterial hypertension (PH), whether primary (P) or secondary (S) due to sys- 
temic sclerosis (SS) has a poor prognosis. Epoprostenol (E) therapy improves symptoms 
and survival in PH, though it is not known if the survival benefit from E is different in PPH 
and SPH patients (pts). 
Methods: Baseline hemodynamics (prior to E therapy) and outcomes were assessed in 
92 PH pts (Grp A: PPH, ~81, age 44.3~ 11.8 years, 87% female, NYHA Class III/ IV 571 
28%; Grp B: SPH, n=31, age 52.8i 11 years, 74% female, NYHA Class III/ IV 45132%) 
treated with E infusion. Both Grps had normal baseline resting left ventricular ejection 
fraction (Grp A: 57+5%, Grp B: 55*5 %). Doses of E were comparable (Grp A: 58i33, 
Grp B: 572.37 ng/kg/min) and pts were followed for 8091 625 days (range 8-3256 days). 
Results: At baseline, Grp A had significantly higher (~~0.05) pulmonary artery (PA) dias- 
tolic (38.6tl0.9/32.8*7.6mmHg), PA Mean (56.4+13.7/49.9+8.8 mmHg) pressures com- 
pared to Grp B. Right Atrial and PA systolic pressures, Cardiac index and pulmonary 
Vascular resistance were comparable in the Grps. During follow-up, 16(26%) Grp A and 
3(10%) Grp B pts underwent pulmonary transplantation and 19(31%) Grp A and 11(36%) 
Grp B pts died. The one, two and five year transplant free survival (figure) in the two Grps 
was comparable (Grp A: 82/59/35%: Grp B: 69/67/38%, p=O.4). 
Conclusion: Lona-term suwival on E theraov is similar in PPH and SPH due to SS. 
despite higher PA pressures in PPH pts at initial presentation. 
domized study is mandatory to confirm this hypothesis. 
Umvariate Analysis Of In-Hospml Risk Factors 
Death Alive 
n=27 n=590 
Age (95% Cl ) 73.4 (66.4- 71.4 (70.4. 
78.4) 72.4) 
Gender (M/P) (n) 8/l 9 239/351 
Previous Thrombo-E mbolism (n) 10 219 
Contra-indication to Thrombolysis (n) 14 228 
Thrombolysis (n) 11 169 
RWLV (95% Cl) 1.00 (0.82- 0.79 (0.77. 
1.17) 0.81) 
Systemic Hypotension (n) 12 101 
P 
0.41 
0.31 
> 0.99 
0.23 
0.20 
< 0.0001 
0.001 
11:45a.m. 
811-4 Effect of Treprostinil Sodium on Circadian Regulation of 
Heart Rate Variability in Primary Pulmonary 
Hypertension 
Martin P. Aosas, Julio Sandoval, Nuria Granados, Fause Attie, Tomas Pulido, Teresa 
Miranda, EfrCn Santos, lnstituto National de Cardiologia lgnacio Chavez, Mexico City, 
MlXiW 
Background: A reduction of heart rate variability (HRV) is now considered as an inde- 
pendent risk factor for morbidity, mortality and severity of several cardiac diseases; how- 
ever, the dynamic sympathovagal modulation on HRV during 24 hr in primary pulmonary 
hypertension (PPH) and the therapeutic impact of Treprostinil Sodium (TS) on this modu- 
lation has not been described. 
Methods: 24 hr-Halter monitoring (HM) were recorded in 15 patients (mean age 34 f 12; 
90% female) with severe PPH (mean pulmonary pressure = 70 + 12 mm Hg), before and 
after three months of therapy with subcutaneous TS. The HRV time and spectral param- 
eters (mean, SDNN, SDANN, rMSSD. PNN50, LF, HF and LF/HF ratio) were analyzed 
during three periods: 24 hr: Day (8-2200) night (23.07:OO) and also during every hour of 
recording (5 min-intervals). 
Results: Circadian rhythm of HRV is clearly disturbed in PPH (increased sympathetic 
tone) as compared to normal control subjects (p < 0.05). Frequency parameters of HRV 
during 24 hr-HM were significantly different before and after long-term subcutaneous TS 
administration (Figure). 
Conclusions: The circadian rhythm of HRV in PPH is lost mainly due to an increase of 
sympathetic tone. This autonomic imbalance may favor the development of arrhythmia, 
